With a view to push its bulk drugs and immuno-suppressant products overseas, RPG Life Sciences is eyeing marketing and distribution tie-ups with foreign companies, a top company official said.
The RPG Group company is eyeing the European market for both its bulk drugs and immuno-suppressants, RPG Life Sciences' Managing Director Ajit Singh Chouhan told PTI here today.
"We have just inked a co-operation pact with Poland's Polpharma, to develop and manufacture Active Pharmaceutical Ingredients (APIs) and in the management of the supply-chain of selected high-value APIs like clopidogrel bisulphate," Chouhan said.
The tie-up will help the RPG Group company push its products in Europe. Both the companies will buy products from each other and sell them in their respective strong markets.
"Both aim to commercialise each other's products. We will also share joint technologies. While RPG's clopidogrel will be marketed by Polpharma in Europe, the RPG company is exploring about 30 of the Polish company's APIs for distribution in India and the Latin American markets," he said.
The company, which seeks to give a boost to its exports, is in talks for marketing tie-ups for selling its products in Germany, Greece and Poland and "some tie-ups are likely to fructify over the next three-months," he said.
More From This Section
Meanwhile, the company clocked a 22 per cent growth in its net sales at Rs 50.66-crore in Q2 FY 11 as against Rs 41.43-crore in the year-ago period. Its PAT rose 40 per cent to Rs 3.91-crore in the quarter as against Rs 2.80-crore in the year-ago period.
"Our growth was driven by new product launches and exports. We launched four products and our exports in H1 FY 11 stood at Rs 28-crore," Chouhan said.
The company is aiming a topline growth of around 20 per cent this fiscal, he said. RPG Life Sciences had clocked a revenue of Rs 163-crore in FY 10.